(Q38167822)

30 August 2017

title

Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance (English)

1 reference

30 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Vaibhav Khare

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Noor Alam

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Ravindra Dhar Dubey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Prem N Gupta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

English

0 references

publication date

3 December 2013

1 reference

Expert Opinion on Drug Delivery

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

121-138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

P-glycoprotein inhibition: the past, the present and the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Three decades of P-gp inhibitors: skimming through several generations and scaffolds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Molecular models of human P-glycoprotein in two different catalytic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Structure-function relationships of multidrug resistance P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

P-glycoprotein: from genomics to mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

ABC of oral bioavailability: transporters as gatekeepers in the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Improving cancer chemotherapy with modulators of ABC drug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Anaemia after enalapril in a child with nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

The effects of pharmaceutical excipients on drug disposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Oral delivery of anticancer drugs: challenges and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Development of a supersaturable SEDDS (S‐SEDDS) formulation of paclitaxel with improved oral bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

ABC transporters in cancer: more than just drug efflux pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Oral delivery of anticancer drugs III: formulation using drug delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Curcumin Enhances Oral Bioavailability and Anti-Tumor Therapeutic Efficacy of Paclitaxel upon Administration in Nanoemulsion Formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Conjugated chitosan as a novel platform for oral delivery of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Nanotechnology: Carrying drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

Overcoming poor oral bioavailability using nanoparticle formulations – opportunities and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.865014

10.1517/17425247.2014.865014

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295039%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference